Loading clinical trials...
Loading clinical trials...
A Phase 2, Open-label, Multi-cohort Study to Assess the Efficacy and Safety of ASP5541 in Participants With Advanced Prostate Cancer
Conditions
Interventions
ASP5541
Prednisone
+3 more
Locations
23
United States
Clearview Cancer Institute
Huntsville, Alabama, United States
H. Lee Moffitt Cancer Center
Tampa, Florida, United States
Associated Urological Specialists
Chicago Ridge, Illinois, United States
New Mexico Oncology Hematology Consultants
Albuquerque, New Mexico, United States
Carolina Urologic Research Center
Myrtle Beach, South Carolina, United States
Tennessee Oncology Nashville
Nashville, Tennessee, United States
Start Date
June 19, 2025
Primary Completion Date
May 31, 2032
Completion Date
May 31, 2032
Last Updated
April 2, 2026
NCT06594926
NCT06257264
NCT03620786
NCT05424783
NCT04693377
NCT06334120
Lead Sponsor
Astellas Pharma Global Development, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions